Theratechnologies Announces Results From Two Posters Presented at ACTHIV 2021 Annual Meeting Highlighting Positive Patient Ex...
May 20 2021 - 7:30AM
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH)
(NASDAQ: THTX), a biopharmaceutical company focused on the
development and commercialization of innovative therapies, today
reported on positive results presented in two separate posters in
conjunction with ACTHIV 2021 virtual conference being held May
20-22, 2021.
The first poster1 included findings from a
survey conducted among 30 Trogarzo® (ibalizumab-uiyk) patients to
assess real-world patient experience and acceptance of IV
administration. The survey found that 100 percent of patients were
either very satisfied or moderately satisfied with their experience
with Trogarzo® (87 and 13 percent respectively). Other highlights
included:
- 60 percent said that their experience with Trogarzo® was better
than expected while 40 percent said it was about the same;
- 93 percent of respondents either found the IV infusion process
very convenient or neutral (70 percent and 23 percent,
respectively);
- 93 percent said they would likely recommend Trogarzo® to
another patient living with HIV;
- 87 percent expressed very high satisfaction with the experience
of receiving an infusion and seeing a healthcare professional every
two weeks; and,
- 80 percent were of the opinion that a touchpoint every two
weeks was likely to support adherence to other HIV
medications.
These findings are in line with conclusions
drawn from a retrospective evaluation conducted by Option Care
Health™, a national alternate site infusion provider, and were also
presented at ACTHIV 20212.
The evaluation demonstrated an overall 98
percent compliance rate with Trogarzo® based on 3,528 infusions
administered to 130 patients between May 2018 and February
2021.
Furthermore, a compliance rate with other
antiretrovirals of 89 percent was observed among Trogarzo®
patients, supporting the patient survey findings.
About
TheratechnologiesTheratechnologies (TSX: TH) (NASDAQ:
THTX) is a biopharmaceutical company focused on the development and
commercialization of innovative therapies addressing unmet medical
needs. Further information about Theratechnologies is available on
the Company's website at www.theratech.com, on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements and
forward-looking information, or, collectively, forward-looking
statements, within the meaning of applicable securities laws, that
are based on our management’s beliefs and assumptions and on
information currently available to our management. You can identify
forward-looking statements by terms such as "may", "will",
"should", "could", “would”, "outlook", "believe", "plan",
"envisage", "anticipate", "expect" and "estimate", or the negatives
of these terms, or variations of them. The forward-looking
statements contained in this press release include, but are not
limited to, statements regarding patients’ satisfaction regarding
the use of Trogarzo® and patients’ compliance to their treatment
regimen.
Forward-looking statements are based upon a
number of assumptions and include, but are not limited to, the
following: patients’ satisfaction from the use of Trogarzo® will
continue to be high, the use of Trogarzo® will allow patients to be
compliant to their treatment regimen, no untoward side effects will
be discovered from the long-term use of Trogarzo® and Trogarzo®
will not be subject to any recall.
Forward-looking statements are subject to a
variety of risks and uncertainties, many of which are beyond our
control that could cause our actual results to differ materially
from those that are disclosed in or implied by the forward-looking
statements contained in this press release. These risks and
uncertainties include, among others, the risk that patients’
satisfaction about Trogarzo® decrease over time, that patients
using Trogarzo® may not adhere to their treatment regimen, that the
IV mode of administration of Trogarzo® may not be perceived by all
patients as convenient, that competition erodes our market share,
that untoward side effects resulting from the long-term use of
Trogarzo® is discovered and that we face product liability
litigations.
We refer current and potential investors to the
“Risk Factors” section of our Annual Information Form dated
February 24, 2021 available on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov as an exhibit to our report on Form 40-F dated
February 25, 2021 under Theratechnologies’ public filings. The
reader is cautioned to consider these and other risks and
uncertainties carefully and not to put undue reliance on
forward-looking statements. Forward-looking statements reflect
current expectations regarding future events and speak only as of
the date of this press release and represent our expectations as of
that date.
We undertake no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise, except as may be required by applicable law.
For media inquiries:
Denis BoucherVice President, Communications and Corporate
Affairs514-336-7800
For investor inquiries:Leah GibsonSenior Director, Investor
Relations617-356-1009
1 Real-world HIV
Patient Experience with Long-Acting Ibalizumab, Brian Beesle et
al.2 Extension of a Retrospective Evaluation of a National
Alternate Site Infusion Provider’s Approach to Parenteral
Ibalizumab-uiyk Compliance, Deborah Dahlke, PharmD, Option Care
Health, Bannockburn, Illinois
Theratechnologies (NASDAQ:THTX)
Historical Stock Chart
From Apr 2024 to May 2024
Theratechnologies (NASDAQ:THTX)
Historical Stock Chart
From May 2023 to May 2024